Cargando…

Pharmacovigilance and the Italian Medicines Agency

The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program...

Descripción completa

Detalles Bibliográficos
Autores principales: Pimpinella, Giuseppe, Tartaglia, Loriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853667/
https://www.ncbi.nlm.nih.gov/pubmed/24347980
http://dx.doi.org/10.4103/0976-500X.120940
_version_ 1782294668288983040
author Pimpinella, Giuseppe
Tartaglia, Loriana
author_facet Pimpinella, Giuseppe
Tartaglia, Loriana
author_sort Pimpinella, Giuseppe
collection PubMed
description The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program for funding active pharmacovigilance projects in the Italian Regions was established by the National law. The AIFA is responsible for the preparation of guidelines aimed at the identification of research areas and for the approval of the projects submitted by the regions. In April 2012, the AIFA started a program of visits at the regional pharmacovigilance centers (RPCs), aimed at monitoring their performances, evaluating the quality of the activities in order to understand the main differences and discrepancies and with a view to start a program of harmonization of the procedures in place. The outcome of the visits program highlighted major differences among the quality management systems of the various centers; hence, AIFA has decided to launch an initiative to promote in the next months the harmonization of procedures. The synergy among AIFA, regional structures, RPCs, and local structure responsible for pharmacovigilance is needed in order to establish a robust pharmacovigilance system working in full compliance with the provisions of the new EU legislation.
format Online
Article
Text
id pubmed-3853667
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-38536672013-12-16 Pharmacovigilance and the Italian Medicines Agency Pimpinella, Giuseppe Tartaglia, Loriana J Pharmacol Pharmacother Commentary The new European Union (EU) regulations on pharmacovigilance require that the national systems are strengthened in order to fit the new requirements. The Italian Pharmacovigilance System, coordinated by the Italian Medicines Agency (AIFA), is made by local and regional structures. In 2007, a program for funding active pharmacovigilance projects in the Italian Regions was established by the National law. The AIFA is responsible for the preparation of guidelines aimed at the identification of research areas and for the approval of the projects submitted by the regions. In April 2012, the AIFA started a program of visits at the regional pharmacovigilance centers (RPCs), aimed at monitoring their performances, evaluating the quality of the activities in order to understand the main differences and discrepancies and with a view to start a program of harmonization of the procedures in place. The outcome of the visits program highlighted major differences among the quality management systems of the various centers; hence, AIFA has decided to launch an initiative to promote in the next months the harmonization of procedures. The synergy among AIFA, regional structures, RPCs, and local structure responsible for pharmacovigilance is needed in order to establish a robust pharmacovigilance system working in full compliance with the provisions of the new EU legislation. Medknow Publications & Media Pvt Ltd 2013-12 /pmc/articles/PMC3853667/ /pubmed/24347980 http://dx.doi.org/10.4103/0976-500X.120940 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Pimpinella, Giuseppe
Tartaglia, Loriana
Pharmacovigilance and the Italian Medicines Agency
title Pharmacovigilance and the Italian Medicines Agency
title_full Pharmacovigilance and the Italian Medicines Agency
title_fullStr Pharmacovigilance and the Italian Medicines Agency
title_full_unstemmed Pharmacovigilance and the Italian Medicines Agency
title_short Pharmacovigilance and the Italian Medicines Agency
title_sort pharmacovigilance and the italian medicines agency
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853667/
https://www.ncbi.nlm.nih.gov/pubmed/24347980
http://dx.doi.org/10.4103/0976-500X.120940
work_keys_str_mv AT pimpinellagiuseppe pharmacovigilanceandtheitalianmedicinesagency
AT tartaglialoriana pharmacovigilanceandtheitalianmedicinesagency